Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 13;21(2):494.
doi: 10.3390/ijms21020494.

Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences

So-Hyeon Hong  1 , Kyung Mook Choi  1
Affiliations
Review

Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences

So-Hyeon Hong et al. Int J Mol Sci. .

Abstract

The prevalence of sarcopenic obesity is increasing worldwide, particularly amongst aging populations. Insulin resistance is the core mechanism of sarcopenic obesity and is also associated with variable cardiometabolic diseases such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Fat accumulation in muscle tissue promotes a proinflammatory cascade and oxidative stress, leading to mitochondrial dysfunction, impaired insulin signaling, and muscle atrophy. To compound the problem, decreased muscle mass aggravates insulin resistance. In addition, the crosstalk between myokines and adipokines leads to negative feedback, which in turn aggravates sarcopenic obesity and insulin resistance. In this review, we focus on the molecular mechanisms linking sarcopenic obesity and insulin resistance with various biological pathways. We also discuss the impact and mechanism of sarcopenic obesity and insulin resistance on cardiometabolic disease.

Keywords: cardiometabolic disease; insulin resistance; sarcopenic obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. United Nations . World Population Prospects: The 2017 Revision, Key Findings and Advance Tables. United Nations; New York, NY, USA: 2017.
    1. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyere O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., et al. Writing Group for the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. doi: 10.1093/ageing/afy169. - DOI - PMC - PubMed
    1. Roubenoff R. Sarcopenic obesity: The confluence of two epidemics. Obes. Res. 2004;12:887–888. doi: 10.1038/oby.2004.107. - DOI - PubMed
    1. Kim Y., White T., Wijndaele K., Sharp S.J., Wareham N.J., Brage S. Adiposity and grip strength as long-term predictors of objectively measured physical activity in 93,015 adults: The UK Biobank study. Int. J. Obes. 2017;41:1361. doi: 10.1038/ijo.2017.122. - DOI - PMC - PubMed
    1. Ma J., Hwang S.J., McMahon G.M., Curhan G.C., Mclean R.R., Murabito J.M., Fox C.S. Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity. Obesity. 2016;24:526–534. doi: 10.1002/oby.21356. - DOI - PubMed

MeSH terms